Free Trial
NASDAQ:INVO

INVO Bioscience (INVO) Stock Price, News & Analysis

INVO Bioscience logo
$1.72 -0.01 (-0.58%)
As of 04/10/2025

About INVO Bioscience Stock (NASDAQ:INVO)

Key Stats

Today's Range
$1.60
$1.75
50-Day Range
$0.20
$2.74
52-Week Range
$0.63
$3.50
Volume
64,185 shs
Average Volume
1.59 million shs
Market Capitalization
$6.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.

Remove Ads
Receive INVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for INVO Bioscience and its competitors with MarketBeat's FREE daily newsletter.

INVO Stock News Headlines

NAYA Biosciences Inc trading halted, news pending
NAYA Biosciences to effect 1-for-12 reverse split
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
My friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92% win rate trading system is built to profit in any market – whether Bitcoin is mooning, correcting, or chopping sideways. No more guessing. No more stress. Just precision trades that put you in control.
NAYA Biosciences supports executive order on fertility treatment access
NAYA Biosciences To Raise $9.5 Mln Through Public Offering Of Units
NAYA Biosciences to present insights into mode of action of NY-303
NAYA Biosciences Inc (INVO)
See More Headlines

INVO Stock Analysis - Frequently Asked Questions

INVO Bioscience's stock was trading at $0.81 at the beginning of the year. Since then, INVO shares have increased by 112.3% and is now trading at $1.72.
View the best growth stocks for 2025 here
.

INVO Bioscience, Inc. (NASDAQ:INVO) issued its quarterly earnings results on Monday, November, 15th. The company reported ($4.80) EPS for the quarter, missing the consensus estimate of ($4.00) by $0.80. The company earned $0.22 million during the quarter, compared to analysts' expectations of $0.25 million.

INVO Bioscience shares reverse split before market open on Thursday, July 27th 2023. The 1-20 reverse split was announced on Thursday, July 27th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of INVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that INVO Bioscience investors own include NVIDIA (NVDA), NIO (NIO), Tesla (TSLA), Meta Platforms (META), Nikola (NKLA), Broadcom (AVGO) and Bilibili (BILI).

Company Calendar

Last Earnings
11/15/2021
Today
4/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:INVO
Fax
N/A
Employees
25
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-8,030,000.00
Net Margins
-122.79%
Pretax Margin
-122.32%

Debt

Sales & Book Value

Annual Sales
$5.77 million
Price / Cash Flow
N/A
Book Value
($2.06) per share
Price / Book
-0.83

Miscellaneous

Free Float
3,769,000
Market Cap
$6.55 million
Optionable
No Data
Beta
1.43
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:INVO) was last updated on 4/12/2025 by MarketBeat.com Staff
From Our Partners